The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.
A sale of rights to royalties for sale of the product which would have otherwise been due to the licensor…
A recent study (report: Royalty Financing Terms and Agreements) has shown a significant increase in the use of royalty and revenues based financing as an alternative way for biotechs to raise finance
This article talks about the industry trend analysis of signing royalty and revenue financing deals among life science sectors
A royalty created where none had previously existed. The royalty stream is generated from future sales …
A royalty created where none had previously existed. The royalty stream is generated from future…
PDL Biopharma, formerly known as Protein Design labs, is headquartered in Nevada.
Royalty Pharma has raised its bid for Elan again. With sum m&a value now sitting at $6.7 billion with options bringing the overall deal value to $8 billion.
Offer for $11.25 or less per share, substantially undervalues the company according to Elan execs
Royalty Pharma announces firm acquisition offer to acquire Elan, with a $12 a share proposal
Alitair Pharmaceuticals has retained Finn, Warnke & Gayton, to sell two Alitair patents and an associated royalty stream at a sealed bid sale on May 24, 2013
Sorry, your search returned no results.
ImmunoGen announced a $200 million non-dilutive royalty transaction with funds managed by TPG Special Situations Partners
Royalty Pharma announced its acquisition of royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics
DRI Capital and Rush University Medical Center announced that Drug Royalty III, DRI has purchased Rush’s royalties relating to worldwide sales of Ampyra for approximately $42 million.
Supernus Pharmaceuticals announced the execution of a royalty financing agreement with HealthCare Royalty Partners.
Ophthotech has received payment of approximately $41.7 million in a second tranche in royalty financing from Novo.
Royalty Pharma has acquired an additional interest in the royalty financing to the former shareholders of Fumapharm AG for $510 million in cash.
Royalty Pharma has sold it’s $485 million interest in Ibrutinib to Aisling Capital and Clarus Ventures in a royalty financing round.
Capital Royalty announced the final closing of Capital Royalty Partners II with $805 million in equity financing.
VIVUS has entered into a $110 million non-equity financing with an investment fund managed by Pharmakon Advisors.